GLP-1s for Fatty Liver Disease (MASH): Wegovy Is Now FDA-Approved

For millions of Americans with fatty liver disease, a GLP-1 medication isn't just about weight loss anymore — it's a direct treatment for their liver condition. Wegovy's August 2025 FDA approval for MASH marked one of the most significant expansions of GLP-1 therapy beyond obesity, and it could change how your insurance company views your prescription.

What Is MASH?

MASH (metabolic dysfunction-associated steatohepatitis) is the newer name for what was previously called NASH (non-alcoholic steatohepatitis). It's a progressive form of fatty liver disease where fat accumulation causes liver inflammation and damage.

Here's the progression path: healthy liver → fatty liver (steatosis) → MASH (inflammation + damage) → fibrosis (scarring) → cirrhosis → liver failure or liver cancer. MASH sits at the critical intervention point — where the disease is actively damaging the liver but hasn't yet progressed to irreversible cirrhosis.

An estimated 5-6% of US adults have MASH. Until recently, the only proven treatment was weight loss through lifestyle changes — difficult to achieve and harder to maintain. The first-ever MASH drug (resmetirom/Rezdiffra) was approved in March 2024, and Wegovy followed in August 2025 as the first GLP-1 approved for this indication.

The ESSENCE Trial: Landmark Results

The FDA approval was based on the Phase 3 ESSENCE trial, published in the New England Journal of Medicine in April 2025. The trial enrolled adults with biopsy-confirmed MASH and moderate-to-advanced liver fibrosis (stages F2-F3) — the patients who need intervention most urgently.

Nearly two-thirds of patients on Wegovy saw their liver inflammation resolve. Over a third experienced actual improvement in liver scarring — meaning the disease wasn't just stopping, it was reversing. These are remarkable numbers for a condition that had almost no pharmacological treatment options a year ago.

Why MASH Responds to GLP-1 Treatment

The connection between obesity, metabolic dysfunction, and liver disease is direct. Excess visceral fat drives insulin resistance, which promotes fat accumulation in liver cells. That fat triggers inflammation, and chronic inflammation leads to fibrosis.

GLP-1 medications address MASH through multiple mechanisms: weight loss reduces liver fat directly, improved insulin sensitivity breaks the metabolic cycle driving fat accumulation, and there's emerging evidence that GLP-1 receptor activation has direct anti-inflammatory effects on liver tissue independent of weight loss.

The ESSENCE trial showed significant liver improvement even in patients with moderate weight loss, suggesting the direct metabolic effects contribute beyond just the pounds lost.

The Insurance Game-Changer

This is where the MASH approval gets practical. Many insurance plans that won't cover GLP-1s for weight management will cover them for approved medical conditions. With MASH now an FDA-approved indication for Wegovy, patients diagnosed with MASH have a new coverage pathway.

If you've been paying out of pocket for a GLP-1 and you have (or suspect you have) fatty liver disease, ask your provider about MASH screening. Diagnosis typically involves blood tests (liver enzymes, FIB-4 score) and may include imaging (FibroScan) or biopsy for staging. A confirmed MASH diagnosis with F2-F3 fibrosis could qualify you for insurance coverage of Wegovy under the liver disease indication.

MASH Treatment Landscape in 2026

Wegovy isn't the only option for MASH, but it's the most compelling for patients who also need weight management:

Rezdiffra (resmetirom) was the first drug approved specifically for MASH (March 2024). It targets thyroid hormone receptor beta to reduce liver fat. It does not cause weight loss — it's a liver-specific treatment.

Wegovy (semaglutide 2.4mg) addresses both the liver disease and the underlying metabolic dysfunction driving it. For patients with obesity and MASH, it treats two conditions with one medication.

Zepbound (tirzepatide) has shown strong liver improvement in trials (including SYNERGY-NASH), but does not yet have an FDA-approved MASH indication. Data is expected to support a future submission.

Monitoring Your Liver on GLP-1 Therapy

Whether or not you have diagnosed MASH, liver enzyme monitoring is increasingly recommended for GLP-1 patients. Your provider should check baseline liver function tests (ALT, AST) before starting treatment and monitor periodically. Improvements in liver enzymes are often one of the early signs that GLP-1 therapy is working metabolically — sometimes visible before significant weight loss appears on the scale.

The Bottom Line

The MASH approval represents GLP-1 medications evolving beyond “weight loss drugs” into comprehensive metabolic health treatments. For patients with fatty liver disease — including the millions who don't yet know they have it — this is a treatment breakthrough and a potential pathway to insurance coverage.

Combined with the cardiovascular protection (SELECT trial), kidney protection (FLOW trial), sleep apnea treatment (Zepbound), and now liver disease treatment, GLP-1s are building a case as perhaps the most broadly beneficial drug class introduced in the past decade.